Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Erasca, Inc.
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)
Sensei Biotherapeutics, Inc.
Theratechnologies
SOLTI Breast Cancer Research Group
Salubris Biotherapeutics Inc